ANVS Projected Dividend Yield
Annovis Bio Inc ( NYSE : ANVS )Annovis Bio, Inc. is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer's disease (AD), Parkinson's disease (PD) and other chronic neurodegenerative diseases. Co. is developing its lead product candidate, Buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. Its product candidate ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after traumatic brain injury (TBI) and/or stroke. 21 YEAR PERFORMANCE RESULTS |
ANVS Dividend History Detail ANVS Dividend News ANVS Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |